TScan Therapeutics, Inc.
TCRXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeTScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company carries a $13.3M market cap, placing it firmly in the micro-cap category. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Market Cap
$13.3M
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
-0.35
EPS (TTM)
$-0.91
EPS (Fwd)
$-0.57
ROE
-95.8%
ROA
-31.5%
Cash
$100.2M
Total Debt
$90.9M
Free CF
-$79.9M
52W Change
-91.2%
Annual Financials
Cash vs Debt
Where TCRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TCRX finished 74.70% below its 150-day moving average ($0.83) and 76.40% below its 200-day moving average ($0.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TCRX overbought or oversold?
At the October 20, 2026 close, TCRX's RSI(14) was 23.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $100.2M in cash comfortably exceeding the $90.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$79.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -95.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $13.5M to $10.3M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TCRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.